Xiao Kai, Liu Qing, Peng Gang, Su Jun, Qin Chao-Ying, Wang Xiang-Yu
Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, Hunan, China.
PeerJ. 2020 Jan 3;8:e8312. doi: 10.7717/peerj.8312. eCollection 2020.
Lower grade glioma (LGG) are a heterogeneous tumor that may develop into high-grade malignant glioma seriously shortens patient survival time. The clinical prognostic biomarker of lower-grade glioma is still lacking. The aim of our study is to explore novel biomarkers for LGG that contribute to distinguish potential malignancy in low-grade glioma, to guide clinical adoption of more rational and effective treatments.
The RNA-seq data for LGG was downloaded from UCSC Xena and the Chinese Glioma Genome Atlas (CGGA). By a robust likelihood-based survival model, least absolute shrinkage and selection operator regression and multivariate Cox regression analysis, we developed a three-gene signature and established a risk score to predict the prognosis of patient with LGG. The three-gene signature was an independent survival predictor compared to other clinical parameters. Based on the signature related risk score system, stratified survival analysis was performed in patients with different age group, gender and pathologic grade. The prognostic signature was validated in the CGGA dataset. Finally, weighted gene co-expression network analysis (WGCNA) was carried out to find the co-expression genes related to the member of the signature and enrichment analysis of the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were conducted for those co-expression network. To prove the efficiency of the model, time-dependent receiver operating characteristic curves of our model and other models are constructed.
In this study, a three-gene signature (WEE1, CRTAC1, SEMA4G) was constructed. Based on the model, the risk score of each patient was calculated with LGG (low-risk vs. high-risk, hazard ratio (HR) = 0.198 (95% CI [0.120-0.325])) and patients in the high-risk group had significantly poorer survival results than those in the low-risk group. Furthermore, the model was validated in the CGGA dataset. Lastly, by WGCNA, we constructed the co-expression network of the three genes and conducted the enrichment of GO and KEGG. Our study identified a three-gene model that showed satisfactory performance in predicting the 1-, 3- and 5-year survival of LGG patients compared to other models and may be a promising independent biomarker of LGG.
低级别胶质瘤(LGG)是一种异质性肿瘤,可能发展为高级别恶性胶质瘤,严重缩短患者生存时间。目前仍缺乏低级别胶质瘤的临床预后生物标志物。本研究的目的是探索用于LGG的新型生物标志物,以有助于区分低级别胶质瘤的潜在恶性程度,指导临床采用更合理有效的治疗方法。
从UCSC Xena和中国胶质瘤基因组图谱(CGGA)下载LGG的RNA测序数据。通过基于稳健似然的生存模型、最小绝对收缩和选择算子回归以及多变量Cox回归分析,我们构建了一个三基因特征并建立了风险评分来预测LGG患者的预后。与其他临床参数相比,该三基因特征是一个独立的生存预测指标。基于与特征相关的风险评分系统,对不同年龄组、性别和病理分级的患者进行分层生存分析。该预后特征在CGGA数据集中得到验证。最后,进行加权基因共表达网络分析(WGCNA)以找到与特征成员相关的共表达基因,并对这些共表达网络进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路的富集分析。为了证明该模型的有效性,构建了我们的模型和其他模型的时间依赖性受试者工作特征曲线。
在本研究中,构建了一个三基因特征(WEE1、CRTAC1、SEMA4G)。基于该模型,计算了每个LGG患者的风险评分(低风险与高风险,风险比(HR)=0.198(95%CI[0.120 - 0.325])),高风险组患者的生存结果明显比低风险组差。此外,该模型在CGGA数据集中得到验证。最后,通过WGCNA,我们构建了这三个基因的共表达网络并进行了GO和KEGG富集分析。我们的研究确定了一个三基因模型,与其他模型相比,该模型在预测LGG患者1年、3年和5年生存率方面表现出令人满意的性能,可能是一种有前景的LGG独立生物标志物。